Harrison Memorial Hospital Completes First Commercial Cordella™ Implant in Three-State Region

Harrison Memorial Hospital (HMH) is proud to announce the launch of Cordella™ implant procedures — a major advancement in the management of heart failure. HMH is the first hospital to complete a commercial (non-study) Cordella implant across Ohio, Kentucky, and Indiana.

Endotronix, a digital health and medical technology company, received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) in August 2019, paving the way for clinical trials and eventual commercial use of the Cordella™ system. According to the company’s area manager, HMH performed the very first commercial Cordella implant in this three-state region — a milestone that highlights the hospital’s commitment to innovation and excellence in cardiovascular care. Dr. Matthew Shotwell, HMH Interventional Cardiologist performs the Cordella implant procedures at HMH.

Heart failure is also a major public health issue — it is one of the leading causes of hospitalization in the United States, accounting for more than 1.2 million hospital admissions each year. (onlinejcf.com). Heart failure means the heart muscle is weaker and cannot pump enough blood to supply the body’s needs. This often leads to shortness of breath, swelling in the legs or feet, and fatigue that can worsen over time.

“Our mission is to provide the highest level of care close to home,” said Dr. Kathy Tussey, HMH Chief Executive Officer. “Introducing the Cordella implant procedure strengthens our heart program and ensures patients have access to the most advanced technology available to manage heart failure in our community.”

The Cordella Sensor is a small wireless device implanted in the pulmonary artery — the vessel that carries blood from the heart to the lungs. It provides continuous data transmission of pulmonary artery pressure and heart function. This real-time information allows physicians to make proactive interventions, adjusting medications or treatment before symptoms become severe — which can reduce hospitalizations and improve outcomes.

“Heart failure can be difficult to manage because symptoms often progress gradually and go unnoticed until they become serious,” said Dr. Matthew Shotwell, HMH Interventional Cardiologist. “With the Cordella system, we receive data that lets us respond quickly and take action before problems escalate. The goal is fewer hospital stays, greater independence for patients, and a better quality of life.”

The Cordella system also provides patients with a tablet and home monitoring tools to check blood pressure, weight, and oxygen levels daily. This keeps patients engaged in their care and keeps their healthcare team informed in real time.

Patient monitoring will be an essential part of the program. Dr. Yaz Daaboul, HMH Cardiologist, will work with the cardiology staff to review the remote data provided by the Cordella system and follow up with patients to adjust medications or treatment plans as needed.

“Completing the first commercial implant across Ohio, Kentucky, and Indiana is an exciting milestone,” added Dr. Shotwell. “This technology allows us to focus on proactive care — preventing crises rather than just reacting to them.”

By adopting this cutting-edge technology, HMH continues to advance cardiovascular care, offering patients access to the latest heart failure management innovations — close to home.

For more information about our HMH Cardiology Services or to make an appointment, please call 859-235-3748.